Valbiotis SA reported a dramatic surge in revenue for fiscal year 2025, with sales climbing to €905,000 – a fivefold increase from the €175,000 recorded in 2024. This growth, particularly pronounced in the fourth quarter with €400,000 in sales representing a 2.3x acceleration from the third quarter, masks underlying structural challenges as the French dietary supplement company navigates a shift in strategy. The company’s performance highlights a deliberate move away from research and development towards aggressive commercialization, a transition that continues to impact its bottom line.
The impressive revenue figures are coupled with a significant net loss of €9.417 million, down slightly from €10.025 million in 2024. This ongoing loss underscores the costs associated with expanding market reach and transitioning to a commercial-focused model. Despite the losses, Valbiotis maintains a cash position of €8.676 million as of December 31, 2025, bolstered by a €5.699 million fundraising effort in June 2025, providing a runway through the end of 2026 without additional financing, according to company statements.
Expanding Product Portfolio and Sales Channels
Valbiotis has been actively expanding its product range and distribution network. The company launched its Cholesterol supplement in 2024 and subsequently added Metabolic Health in February 2025 and Cardio-Circulation in June 2025 to its ValbiotisPRO® line. Initially focused on direct-to-consumer sales through its e-commerce platform, the ValbiotisPLUS® range began a phased rollout in pharmacies starting in October 2025. By year-end, seven supplements were available across both channels. The company reported a 65% pharmacy reorder rate and a 198% increase in the average value of business-to-business (B2B) orders, reaching €471. E-commerce sales saw a 325% increase in customers, totaling 4,030, with an average order value of €85.80 and a 70% customer recommendation rate.
However, the company acknowledges that the full impact of its expanded product line wasn’t realized until the fourth quarter, when the number of products available in pharmacies doubled to ten. This suggests that the first three quarters of the year operated with a limited commercial offering, contributing to the significant revenue jump observed in the final months of 2025.
Strategic Shift: From R&D to Commercialization
A key element of Valbiotis’s strategy has been a substantial reallocation of its budget. Research and development (R&D) spending was reduced by 80%, falling from €4.638 million in 2024 to €921 million in 2025. This reduction is attributed to the completion of major clinical trials and the closure of the company’s research laboratory in Riom. Simultaneously, sales and marketing expenses increased by 18% to €5.140 million, now representing 50% of operational expenses (excluding costs related to share-based payments), up from 30% the previous year. General administrative expenses were too reduced by 32% to €2.096 million through structural efficiencies implemented in the second half of 2024. Overall operational expenses decreased by 30% to €10.540 million.
According to Sébastien Peltier, CEO and Co-Founder of Valbiotis, this shift is intentional and aligned with the company’s roadmap. “We executed our strategy in perfect alignment with our roadmap and within a rigorous financial framework,” Peltier stated in a press release. “We reduced our operating expenses by 30% even as stepping up our commercial and marketing investments.”
International Expansion and Future Outlook
Valbiotis has secured key partnerships to drive international growth. Post-year-end, the company finalized a partnership in Asia (China, Hong Kong, Vietnam, Indonesia, Japan, Taiwan, and Singapore) through a 49% joint venture established in November 2025, and an exclusive distribution agreement in the Middle East in January 2026. These agreements are expected to generate initial revenue in 2026. Within France, Valbiotis’s distribution network includes 474 pharmacies directly and 15 partnerships with pharmaceutical groups, providing access to an additional 3,000 affiliated pharmacies.
Looking ahead to 2026, Valbiotis anticipates continued commercial acceleration, incorporating revenue from its international partnerships. The company has reaffirmed its medium-term goals, targeting revenue exceeding €25 million and positive EBITDA in France by 2027, and surpassing €100 million in revenue with an EBITDA margin of 25-30% by 2030.
Valbiotis’s financial results demonstrate a company in transition, prioritizing commercial growth after a period of intensive research and development. While the company continues to report losses, its strategic shift and expanding international presence position it for potential future profitability. Investors will be closely watching the impact of the new Asian and Middle Eastern partnerships on revenue generation in the coming year.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute financial advice. Investing in securities involves risks, including the potential loss of principal.
Have thoughts on Valbiotis’s strategy? Share your comments below and share this article with your network.
